Study to Test the Efficacy and Safety of Vafidemstat in Adult Borderline Personality Disorder Population

PHASE2CompletedINTERVENTIONAL
Enrollment

210

Participants

Timeline

Start Date

March 26, 2021

Primary Completion Date

October 30, 2023

Study Completion Date

November 13, 2023

Conditions
Borderline Personality Disorder
Interventions
DRUG

vafidemstat

1.2mg capsule

DRUG

Placebo

placebo capsule

Trial Locations (21)

1680

Medical Center Intermedika, Sofia

3400

Clinical center Kragujevac, Kragujevac

9000

Medical Center Hera EOOD - Psychiatry Office, Sofia

"DCC Mladost-M Ltd, Psychiatr", Varna

10128

The Medical Research Network, New York

10629

Emovis GmbH, Berlin

11000

"Clinic for psychiatric disorders Laza Lazarevic", Belgrade

Clinical center of Serbia, Belgrade

11516

Neurobehavioral Research Inc., Cedarhurst

28040

Hospital Clínico San Carlos, Madrid

33012

New Life Medical Research Center, Hialeah

33165

Phoenix Medical Research LLC, Miami

60123

Revive Research Institute, Elgin

80336

Klinik fur Psychiatrie und Psychotherapie, LMU, München

92056

Excell Research Inc, Oceanside

Excell Research, Inc., Oceanside

98201

Core Clinical Research, Everett

60637-1426

University of Chicago Institutional Review Board, Chicago

02472

Adams Clinical Trials, LLC, Watertown

08002

Center for Emotioal Fitness, Cherry Hill

08035

Hospital Vall d'Hebron, Barcelona

Sponsors
All Listed Sponsors
lead

Oryzon Genomics S.A.

INDUSTRY

NCT04932291 - Study to Test the Efficacy and Safety of Vafidemstat in Adult Borderline Personality Disorder Population | Biotech Hunter | Biotech Hunter